Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit

• Published in: ACS chemical biology 2023-02, Vol.18 (2), p.296-303
• Main Authors: Kawatkar, Aarti, Clark, Roger A., Hopcroft, Lorna, Roaquin, Debora Ann, Tomlinson, Ronald, Zuhl, Andrea M., Lamont, Gillian M., Kettle, Jason G., Critchlow, Susan E., Castaldi, M. Paola, Goldberg, Frederick W., Zhang, Andrew X.
• Format: Article
• Language: English
• Subjects: Biological Transport; Biology; Cell Line, Tumor; Cell Proliferation; Lactic Acid - metabolism
• ISSN: 1554-8929; 1554-8937
• DOI: 10.1021/acschembio.2c00666

Lactic acid transport is a key process maintaining glycolytic flux in tumors. Inhibition of this process will result in glycolytic shutdown, impacting on cell growth and survival and thus has been pursued as a therapeutic approach for cancers. Using a cell-based screen in a MCT4-dependent cell line, we identified and optimized compounds for their ability to inhibit the efflux of intracellular lactic acid with good physical and pharmacokinetic properties. To deconvolute the mechanism of lactic acid efflux inhibition, we have developed three assays to measure cellular target engagement. Specifically, we synthesized a biologically active photoaffinity probe (IC50 < 10 nM), and using this probe, we demonstrated selective engagement of MCT4 of our parent molecule through a combination of confocal microscopy and in-cell chemoproteomics. As an orthogonal assay, the cellular thermal shift assay (CETSA) confirmed binding to MCT4 in the cellular system. Comparisons of lactic acid efflux potencies in cells with differential expression of MCT family members further confirmed that the optimized compounds inhibit the efflux of lactic acid through the inhibition of MCT4. Taken together, these data demonstrate the power of orthogonal chemical biology methods to determine cellular target engagement, particularly for proteins not readily amenable to traditional biophysical methods.